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1,25-dihydroxyvitaminD3 (1,25(OH)2D3), has potent anti-inﬂammatory effects, including suppression of
IL-17 þ and IFNgþ T cells implicated in rheumatoid arthritis (RA), but efﬁcacy at the site of active disease
is unclear. To investigate this, T cells from synovial ﬂuid (SF) and paired blood of patients with active RA
were studied. 1,25(OH)2D3 had signiﬁcantly less suppressive effect on Th17 cells (IL-17þIFNg-) and
Th17.1 cells (IL-17þIFNgþ) from SF compared to those from blood, and had no effect on SF CD4þ or CD8þ
IFNgþ T cell frequencies. Memory T cells (CD45ROþ) predominate in SF, and 1,25(OH)2D3 had less effect
on memory T cells relative to naïve (CD45RAþ) T cells. RT-PCR and ﬂow cytometry showed that this was
not due to decreased expression of the vitamin D receptor or its transcription partners in memory T cells.
Further studies using stimulated CD4þ T cells sorted according to IL-17 and IFNg expression conﬁrmed
the ability of 1,25(OH)2D3 to suppress pre-existing cytokines. However, 1,25(OH)2D3 was most effective at
suppressing de novo IL-17 and IFNg induction. Correspondingly, T cell responses to 1,25(OH)2D3 corre-
lated directly with capacity for phenotype change, which was lower in cells from SF compared to blood.
These ﬁndings indicate that anti-inﬂammatory effects of 1,25(OH)2D3 in active RA are impaired because
of reduced effects on phenotype-committed, inﬂammatory memory T cells that are enriched in SF.
Restoration of 1,25(OH)2D3 responses in memory T cells may provide a new strategy for treatment of
inﬂammatory diseases such as RA.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The active form of vitamin D, 1,25-dihydroxyvitamin D3
(1,25(OH)2D3) promotes anti-inﬂammatory responses in a diverse
array of cell types, supporting the potential use of vitamin D in the
prevention and/or treatment of inﬂammatory disorders [1,2]. In
previous studies we have shown that anti-inﬂammatory actions of
vitamin D may occur indirectly through localized synthesis of
1,25(OH)2D3, and reduced expression of major histocompatibility
and co-stimulatory molecules by antigen-presenting dendritic cellsystems Research, Level 2, IBR,
B15 2TT, UK.
son).
r Ltd. This is an open access article(DCs), monocytes and macrophages [3e6]. However, 1,25(OH)2D3
can also act directly on T-lymphocytes (T cells), inhibiting their
proliferation [7], especially under conditions of weak co-
stimulation [8], and suppressing their production of pro-
inﬂammatory cytokines such as IFNg, IL-17 and IL-21 [9e13],
whilst promoting their expression of regulatory markers including
CTLA-4, FoxP3, and IL-10 [13] even in the presence of pro-
inﬂammatory cytokines [14]. Crucially almost all of these obser-
vations have stemmed from experiments using T cells from the
blood of healthy donors andmuch less is known about the effects of
1,25(OH)2D3 in established inﬂammatory disease, especially its ef-
fects uponTcells from inﬂamed compartments such as the joint of a
patient with rheumatoid arthritis (RA).
Epidemiology suggests that many autoimmune diseases andunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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with vitamin D-deﬁciency [15e17]. Vitamin D metabolites such as
1,25(OH)2D3 may therefore provide an alternative strategy for the
prevention and/or treatment of RA [18], possibly as an adjunct to
existing RA therapies [8]. Previous studies have highlighted aber-
rant metabolism of vitamin D in disease-affected synovial ﬂuid (SF)
from RA patients [19], but the impact of 1,25(OH)2D3 on Tcells from
the site of inﬂammation, the inﬂamed joint, has yet to be studied.
IFNgþ Th1 cells and IL-17þ Th17 cells are regarded as important
mediators of chronic synovial inﬂammation. Increased levels of
their hallmark and differentiating cytokines are found in the serum
and synovial ﬂuid of patients relative to controls [20], and elevated
frequencies of both have been detected in the blood and joints of RA
patients [21]. IFNg produced by Th1 cells promotes APC maturation
whilst IL-17 has pleiotropic effects, driving ﬁbroblast-like syno-
viocytes (FLS) to release pro-inﬂammatory cytokines and chemo-
kines [22], that further amplify the inﬂammation by facilitating the
recruitment and retention of immune cells, including
CCR5þCXCR3þ Th1 cells [23,24] and CCR6þ Th17 [25,26] cells into
the joint. IL-17 from Th17 cells also promotes cartilage and bone
resorption by stimulating MMP release from FLS [22] and the in-
duction of RANKL on FLS and osteoblasts leading to activation of
RANK þ osteoclasts [27]. The ability of 1,25(OH)2D3 to affect T cell
function is important in RA, as T cells accumulate in the RA syno-
vium and genetic risk factors for RA are largely related to T cell
activation [20e25]. The aim of the current study was to investigate
further the potential use of vitamin D as a therapy for RA, by
determining whether anti-inﬂammatory effects of 1,25(OH)2D3 are
achievable on T cells from the site of inﬂammation.
2. Materials and methods
Patients were recruited for the study if they fulﬁlled 1987 ACR
criteria for RA [28]. All patients and age and gender-matched
healthy controls gave full written consent. Patient demographics
are summarized in Table 1. Ethical approval for the work was
granted by Solihull Research Ethics Committee (REC reference
number 07/Q2706/2) and the University of Birmingham Ethics
Committee (ERN_14-0446). For naïve and memory T cell compari-
son studies, as well for as cytokine-expression cell capture exper-
iments, cells were isolated from fully anonymysed leukocyte cones
obtained from the National Blood Service, Birmingham, UK.
2.1. Cell isolation and culture
Synovial Fluid (SF) was extracted by ultrasound guidance asTable 1
Patient Demographics: Disease activity score 28 based upon C Reactive Protein (CRP) (DA
citrullinated peptide antibody (anti-CCP); conventional synthetic and biological disease
Patient Gender Age (yrs) Disease duration (yrs) DAS28 (CRP) CRP (mg/dl) ESR (mm
1 f 65 4 2.89 <5 37
2 m 85 4 5.18 138 NA
3 m 65 3 4.88 81 72
4 f 65 4 4.84 10 41
5 m 42 6 5.30 95 27
6 f 40 <1 3.18 14 26
7 m 47 2 5.48 34 NA
8 m 42 6 4.19 23 7
9 f 40 <1 4.73 59 57
10 m 42 6 4.82 14 2
11 m 45 4 8.21 166 130
12 m 59 3 6.21 29 26
13 f 55 5 5.08 19 42
14 f 35 5 5.83 20 17
15 f 68 27 5.10 86 46described previously [29] or by palpation guidance. Prior to SF
Mononuclear Cell (SFMC) isolation, SF was treated with hyaluron-
idase (10U/ml) for 30 min at 37 C. PBMCs and SFMCs were isolated
by the Ficoll-Paque PLUS method of density gradient centrifugation
(GE Healthcare). SF was layered on Ficoll-Paque PLUS undiluted,
fresh blood was diluted 1:1 with PBS and leukocyte cones were
diluted 1:4 with PBS before layering. Isolated SFMCs and PBMCs
were cultured at 37 C, 5% CO2 in RPMI 1640 medium and sup-
plemented with 1% penicillin and streptomycin, 2 mM L-glutamine,
and 5% self-serum or SF that was pre-ﬁltered through a 22 mm ﬁlter.
For ex vivo cytokine expression analysis, cells were allowed to rest
overnight at 1  106 cells/ml without stimulation before being
stimulated for 6e7 h with phorbol myristate acetate (PMA) (50 ng/
ml) and ionomycin (1 mM). Brefeldin A (10 mg/ml) was added during
the last 4e5 h. For stimulationmononuclear cells were treatedwith
anti-CD3 (0.5 mg/ml, clone OKT3) at 2.5  105 cells/ml. 1,25(OH)2D3
was added to cultures at 100 nM and ethanol used as a vehicle
control at 0.1%. At seven days, cells were restimulated with PMA/
ionomycin in the presence of brefeldin A for cytokine expression
analysis by ﬂow cytometry.
For experiments using isolated CD45RA þ CD4þ naïve T cells,
CD45RO þ CD4þ memory T cells and CD14 þ monocytes, cells were
enriched by negative selection using cell separation reagents
(StemCell Technologies and Biolegend). For 24 h post-stimulation
analysis of gene expression, T cells were stimulated with anti-
CD3/CD28 dynabeads (Life Technologies) at a ratio of 1 bead: 2 T
cells in medium supplemented with 5% human AB serum (TCS
Biosciences, Buckingham UK). For longer-term stimulations a ratio
of 1 bead: 4 T cells was used. Where T cells were stimulated with
monocytes, a ratio of 1 monocyte: 4 T cells and OKT3 0.5 mg/ml was
used.
2.2. Isolation and culture of Th17, Th17.1 and Th1 cells
Expanded populations of Th17, Th17.1 and Th1 cells were
generated by stimulating magnetically puriﬁed monocytes and
CD4þ T cells at 1:5 ratio with 0.5 mg/ml antiCD3 for seven days. IL-
17-PE and IFNg-APC cytokine secretion detection kits (Miltenyi
Biotech) were used to label live Th17, Th17.1 and Th1 cells. In brief,
cultures were re-stimulated with Phorbol 12,13-dibutyrate (PDBu)
(10 ng/ml) and ionomycin (1 nM) for 2 h before labeling with IL-17
and IFNg catch reagents on ice at 10  106 cells/80 ml MACS buffer
for 5 mins. Cells were transferred to pre-warmed RPMI and incu-
bated for 40 mins at 37 C at 4  105 cells/ml under continual
rotation. Cells were then diluted 1:1 with ice-cold MACS buffer and
chilled on ice for 10 min before centrifuging and labelling with IL-S28 (CRP); Erythrocyte sedimentation rate (ESR); Rheumatoid Factor (RF); anti-cyclic
modifying anti-rheumatic drugs (csDMARDs/bDMARDs).
/hr) RF (±) Anti-CCP (±) cs/DMARDs/bDMARDs
þ e methotrexate, rituximab
e þ Sulfasalazine, prednisolone
þ þ nil
þ e methotrexate, rituximab
e NA sulfasalazine, methotrexate, prednisolone, tocilizumab
e e methotrexate
þ NA methotrexate
þ þ methotrexate, prednisolone, rituximab
e e sulfasalazine
e NA sulfasalazine, methotrexate, prednisolone, tocilizumab
e e nil
þ þ methotrexate
þ e methotrexate, sulfasalazine
þ þ methotrexate
þ þ methotrexate, etanercept
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during the ﬁnal 10 min. After washing, Th17, Th17.1, Th1 and
cytokine double-negative (DN) populations were collected into
RPMI by FACS. Sorted T cells were then stimulated with negatively
enriched (StemCell Technologies) and CD14þ FACS-puriﬁed allo-
genic monocytes at 1:4 ratio and 0.5 mg/ml anti-CD3 (OKT3) for 2
days in the presence of 40units/ml IL-2 (Immunotools) ± 100 nM
1,25(OH)2D3. Cell purities were >99% for Th17, Th1, DN and
monocytes and >90% for Th17.1 cells.
2.3. Flow cytometry
CD45-ROþ frequencies were assessed directly ex vivo by surface
staining at 4 C in PBS with antiCD45RO-FITC, CD3-PE and CD4-APC
(all from BD Biosciences). For post-stimulation cultures, dead cells
were labelled with near-IR LIVE/DEAD ﬁxable dead cell stain (Mo-
lecular Probes, Life Technologies) before ﬁxation. For analysis of
regulatory markers: CTLA-4, Foxp3 and CD25, cells were ﬁxed,
permeabilised and stained with ebioscience/Thermoﬁsher Foxp3
staining buffers according to the manufacturer's instructions. For
analysis of cytokine expression, PMA/ionomycin-restimulated cells
were ﬁxedwith 3% paraformaldehyde in PBS for 12min followed by
a 5-minute wash with PBS under centrifugation. Fixed cells were
permeabilised with 0.1% saponin (Acros Organics) prepared in PBS
and stained with IL-17-PE, IFNg-e450, IL-21-APC, CD3-PERCP, CD4-
FITC. For all studies cells were acquired on a Dako Cyan ﬂow cy-
tometer (Dako Cytomation) and data analysed using FlowJo soft-
ware (Tree Star version 8.8.6). All antibodies were purchased from
ebioscience/Thermoﬁsher or BD Biosciences and expression quan-
tiﬁed relative to the appropriate isotype control.
2.4. Quantitative real-time PCR
Total RNAwas extracted by phenol/chloroformmethod after cell
lysis in TRIzol (Life Technologies/Invitrogen). 0.3e0.5 mg RNA was
reverse transcribed with random hexamers using TaqMan reverse
transcription reagents (Thermoﬁsher/Applied Biosystems). Quan-
titative real-time PCR for 18S rRNA, VDR, RXR, DRIP-205, NcOA1,
NCOR1 and NCOR2, IL-17 or IFNg was then performed on an
Applied Biosystems 7900 machine using assays on demand from
Applied Biosystems: 18S rRNA, (4319413E); VDR (Hs00172113_m1);
RXR (Hs01067640_m1), NCoR1 (Hs01094540_m1), NCoR2
(Hs00196955_m1), DRIP205 (Hs01062349_m1), NCoA1
(Hs00186661_m1); IL-17 (Hs99999082_m1) and
IFNg(HS00989291_m1). Ampliﬁcation of cDNAs involved incuba-
tion at 50 C for 2 min and 95 C for 10 min followed by 40 cycles of
95 C for 15 s and 60 C for 1 min. VDR mRNA expression was then
calculated relative to 18S rRNA using the delta Ct method as
described previously [30].
2.5. Statistical analysis
GraphPad Prism 5.0a software (GraphPad) was used for graph-
ical summary and statistical analysis. For analysis of normality and
Q-Q plot inspection SPSS statistics version 22 was used. Non-
parametric Wilcoxon tests were used to test signiﬁcance between
two conditions. To test interactions between 1,25(OH)2D3 and cell
source location repeated measures two factor within subject
analysis with Huynf-Feldt correction was performed. The Shapiro-
Wilk normality test and inspection of normal Q-Q plots were
used to conﬁrm that the data could be tested with these parametric
models. For data sets that did not pass the normality test (VDR
mRNA) the data were log10 transformed, since by this trans-
formation the residuals from the mean became normally
distributed.3. Results
3.1. Anti-inﬂammatory effects of 1,25(OH)2D3 are reduced in
synovial ﬂuid T cells
To determine whether T cells from patients with active RA are
sensitive to the anti-inﬂammatory effects of 1,25(OH)2D3, periph-
eral blood mononuclear cells (PBMC) from the blood of healthy
controls and established RA patients, as well as synovial ﬂuid (SF)
mononuclear cells (SFMC) from RA patients, were stimulated with
anti-CD3 in the presence or absence of 1,25(OH)2D3 for seven days
and the frequency of CD4þ T cells expressing IL-17 or IFNg
measured by ﬂow cytometry (Fig. 1A and B). 1,25(OH)2D3 decreased
IL-17 þ and IFNgþ T cell frequencies in HC and RA PBMCs. It also
reduced frequencies of IL-17 þ T cells in SFMC cultures. However
1,25(OH)2D3 had no effect on the frequency of IFNgþ T cells in
SFMCs (Fig. 1B). Further classifying CD4þ T cells according to their
combined expression of IL-17 and IFNg revealed signiﬁcantly
greater suppressive effects of 1,25(OH)2D3 on Th17 (IL-17þIFNg-)
and Th17.1 (IL-17þIFNgþ) T cells in RA blood relative to SF, whilst
Th1 (IL-17-IFNgþ) frequencies were not affected by 1,25(OH)2D3 in
blood or SF (Fig. 1C). Thus Th17 and Th17.1 populations from the
inﬂamed joints of RA patients are less sensitive to the anti-
inﬂammatory effects of 1,25(OH)2D3 than equivalent circulating T
cells. Similar results were also obtained with CD8þ T cells (Fig. S1),
where 1,25(OH)2D3 decreased IL-17 þ CD8þ frequencies in HC and
RA PBMC, as well as SFMC. However, 1,25(OH)2D3 had no effect on
the frequency of IFNgþ CD8þ T cells in RA PBMC or SFMC.
3.2. Effects of 1,25(OH)2D3 are greater on blood naïve versus
memory T cells
Consistent with previous studies [31], only 47% (±12%) T cells
isolated from blood were memory (CD45ROþ). By contrast, 98%
(±2%) SF T cells were CD45ROþ (Fig. S2). We therefore determined
whether the decreased effect of 1,25(OH)2D3 upon SF T cells could
be attributed to differences between memory and naïve T cells. As
shown in Fig. 2A and Fig. S3, IL-17 þ and IFNgþ T cells were more
abundant in memory T cell populations. Treatment with
1,25(OH)2D3 suppressed IFNgþ and IL-17 þ frequencies in both
naïve and memory subsets. For IL-17, 1,25(OH)2D3 had equal effect
on naïve and memory T cells whereas the effect of 1,25(OH)2D3 on
IFNg expression was greatest for naïve T cells (Fig. 2B). 1,25(OH)2D3
also had greatest effect upon IL-21 and CTLA-4 expression in naïve T
cells compared to memory T cells, with 1,25(OH)2D3 inducing
CTLA4 in naïve T cells but having no effect on memory T cells
(Fig. 2B and Fig. S3).
As it is unclear how many rounds of stimulation circulating
memory T cells have experienced in vivo, we also compared the
effect of 1,25(OH)2D3 on naïve and memory T cells during
sequential rounds of stimulation (Fig. S4). Analysis of three cyto-
kines (IL-17, IFNg, and IL-21) showed that 1,25(OH)2D3 was more
effective in naïve versus memory T cells at the ﬁrst round of
stimulation, but this difference in sensitivity was lost following the
second round of T cell stimulation. These data support the concept
that induction of a memory T cell phenotype reduces the anti-
inﬂammatory effects of 1,25(OH)2D3 on T cells, which may in part
explain the differences in 1,25(OH)2D3 responses between blood
and SF T cells.
3.3. 1,25(OH)2D3 signaling components in naïve versus memory T
cells
To investigate the underlying basis for reduced 1,25(OH)2D3
responsiveness in memory versus naïve T cells, expression of the
Fig. 1. Anti-inﬂammatory effects of 1,25(OH)2D3 are reduced in T cells from synovial ﬂuid compared to peripheral blood. Mononuclear cells from the peripheral blood of
healthy controls (HC) and the blood and synovial ﬂuid (SF) of RA patients were stimulated with anti-CD3 for seven days in the presence or absence of 1,25(OH)2D3 (þ1,25D) and
frequencies of IL-17 þ and IFNgþ CD4þ T cells quantiﬁed by ﬂow cytometry (A). Representative bivariate plots of IL-17 versus IFNg expression by CD4þ T cells showing IL-17þ/IFNg-
(Th17), IL-17þIFNgþ (Th17.1) and IL-17-IFNgþ (Th1) subsets for cells from RA blood vs RA SF. (B). Signiﬁcant effects of 1,25(OH)2D3 were tested for HC (n ¼ 9), RA blood (n ¼ 12), RA
SF (n ¼ 11) by Wilcoxon matched pairs or Mann Whitney nonparametric tests as appropriate (C). Effect of 1,25(OH)2D3 on Th17, Th17.1 and Th1 populations quantiﬁed by frequency
in respective gate under untreated/1,25D conditions. Signiﬁcance was tested by repeated measures two-way ANOVA. ns ¼ non-signiﬁcant, * ¼ P < 0.05, ** ¼ P < 0.01, *** ¼ P < 0.001.
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heterodimer partner, as well as associated activator/repressor
proteins was assessed. RT-PCR analyses and ﬂowcytometry showed
similar low levels of VDR in unstimulated naïve andmemory Tcells,
with VDR expression increasing in both Tcell populations following
stimulation (p < 0.05 for mRNA and protein in stimulated naïve and
memory T cells versus unstimulated naïve and memory T cells)
(Fig. 3A). Similar to VDR, unstimulated naïve and memory T cells
showed comparable low expression of RXR, but only memory T
cells showed induction of this receptor upon stimulation (Fig. 3B).
In addition to VDR and RXR, several co-regulators participate in
1,25(OH)2D3-mediated transcriptional responses, and these factors
may contribute to variable responses to 1,25(OH)2D3 [32]. However,
analysis of mRNAs for the co-enhancers DRIP205 and NcOA1, and
co-repressors NcoR1 and NcoR2, showed no difference in expres-
sion between naïve and memory T cells (Fig. 3C). The decreased
1,25(OH)2D3 responsiveness of memory versus naïve T cells could
therefore not be attributed to impaired expression of VDR or its
signaling partners.3.4. Effects of 1,25(OH)2D3 in SF versus blood memory T cells
To determinewhether decreased responses to 1,25(OH)2D3 in SF
compared to blood T cells involve differences between memory T
cells from the two compartments, matched CD45RO þ CD4þ
memory T cells from paired blood and SF of RA patients were
stimulated in the presence or absence of 1,25(OH)2D3. Flow
cytometry for IFNg and IL-21 showed decreased anti-inﬂammatoryeffects of 1,25(OH)2D3 in SF versus blood memory T cells, whilst a
non-signiﬁcant trend was observed for IL-17 (Fig. 4A). Flow
cytometry and RT-PCR revealed enhanced VDR expression in
unstimulated memory T cells isolated from SF relative to those
obtained from blood (Fig. 4B and C), consistent with their more
activated (CD69þ) phenotype (Fig. 4C). VDR expression increased
following memory T cell stimulation (p < 0.001 for stimulated
versus unstimulated cells), but there was no signiﬁcant difference
in VDR expression between stimulated blood and stimulated SF
cells (Fig. 4B). By contrast, mRNA for RXR did not differ in blood
versus SF memory T cells in the stimulated or unstimulated state
(Fig. 4B). The co-regulators DRIP205, NcoA1, NcoR1 and NcoR2 also
showed elevated expression in unstimulated memory SF T cells
(Fig. S5), similar to that observed for VDR. Collectively these data
indicate that SF memory T cells are less affected by 1,25(OH)2D3
than memory T cells from blood, but this is not due to impaired
expression of VDR or its signaling partners.3.5. Effects of 1,25(OH)2D3 on Th17, Th17.1 and Th1 cells
To date, reported anti-inﬂammatory effects of 1,25(OH)2D3 have
been based on data frommixed cultures of cytokine-expressing and
non-expressing T cells. Further studies were therefore carried out
to determine the effects of 1,25(OH)2D3 on T cells expressing spe-
ciﬁc cytokines. By combining anti-IL-17-PE and anti-IFNy-APC
cytokine detection reagents, live T cells were labeled according to
their expression of IL-17 and/or IFNg, and Th17, Th17.1, Th1 cells
were obtained by FACS as well as T cells double negative for IL-17
Fig. 2. Effects of 1,25(OH)2D3 are greater on naïve than memory T cells. Naive and memory CD4þ T cells were puriﬁed from the peripheral blood of healthy controls and
stimulated with autologous monocytes and anti-CD3 in the presence or absence of 1,25(OH)2D3 (þ1,25D). Frequency of cells expressing IL-17, IFNg and IL-21 was quantiﬁed at seven
days and expression of CTLA-4 and FoxP3 measured at four days by ﬂow cytometry. (A) Frequencies of cytokine positive cells and CTLA-4 median ﬂuorescence intensity (MFI)
summarised for n ¼ 6 donors for vehicle (closed symbols) and 1,25(OH)2D3 (þ1,25D)-treated cells (open symbols). (B) The effect of 1,25(OH)2D3 on IL-17, IFNg and IL-21 was
compared for naïve and memory T cells by frequency of positive cells under untreated/1,25D conditions. A lower frequency limit of 0.001% was used for these calculations.
1,25(OH)2D3 effect on CTLA-4 was estimated by MFI under 1,25D/untreated conditions. Signiﬁcant differences were tested using Wilcoxon matched pairs tests. ns ¼ non-signiﬁcant,
* ¼ P < 0.05, ** ¼ P < 0.01, *** ¼ P < 0.001.
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sorted populations conﬁrmed cytokine purity of the sorted cells
(Fig. S6). The Th17, Th17.1 and Th1 T cells generated in this manner
were then re-stimulated in the presence or absence of 1,25(OH)2D3
for two days. In vehicle-treated re-stimulated populations, we
observed plasticity of phenotype between Th17, Th17.1 and Th1,including the generation of T cells double negative for IL-17 and
IFNg (Fig. 5A). Th17 cells could give rise to IFNg-expressing T cells,
and Th1 cells could induce IL-17expression. DN cells could also give
rise to IL-17 and IFNg (Fig. 5A).
Treatment with 1,25(OH)2D3 reduced expression of IL-17 or IFNg
in T cells pre-committed to Th17 and Th1 phenotypes respectively,
Fig. 3. Memory and naïve T cells express similar levels of vitamin D response machinery. RNA was puriﬁed from naive and memory CD4þ T cells from the peripheral blood of
healthy controls before and after stimulation with antiCD3/CD28 beads. Regulators of response to 1,25(OH)2D3 including (A) Vitamin D receptor (VDR), (B) Retinoid X Receptor
(RXR), (C) VDR co-regulators: DRIP205, NcoA1, NcoR1 and NcoR2 were measured by qPCR. mRNA expression for each gene is shown relative to matched memory T cells. VDR protein
in T cells was also measured by ﬂow cytometry before and after stimulation with PMA and ionomycin. Stimulated T cells were deﬁned as CD69þ. Statistical signiﬁcance was tested by
repeated measures two-way ANOVA. * ¼ P < 0.05, ** ¼ P < 0.01.
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expression of IL-17 or IFNg (Fig. 5A and B). In Th17 cells,
1,25(OH)2D3-sensitivity was greater for IFNg than IL-17, whilst the
opposite response was observed in Th1 cells. Moreover,
1,25(OH)2D3 actively suppressed the development of Th17, Th17.1
and Th1 populations fromDN Tcells, but had little effect on IL-17 or
IFNg expression in Th17.1 T cells that had pre-existing expression of
both IL-17 and IFNg (Fig. 5B).3.6. Capacity for phenotype change is low in SF T cells
Further studies were carried out to determine if the impaired
response to 1,25(OH)2D3 observed for SF versus blood T cells was
due to differences in T cell phenotype commitment and plasticity.
This was carried out by comparing the cytokine proﬁles of blood
and SF Tcells ex vivo and after stimulation. Therewere few IL-17þ T
cells in blood ex vivo and these were almost exclusively Th17
(Fig. 6A, B and D). IL-17 expression was also low in SF, but this was
evenly distributed across Th17 and Th17.1 populations (Fig. 6D).
Compared to IL-17, considerably more T cells expressed IFNg ex vivo
in blood and SF, however, the frequency of IFNgþ cells was much
higher in SF compared to paired blood. Culture of T cells from blood
for 7 days resulted in signiﬁcant expansion of IL-17 þ T cells (12-
fold) (Fig. 6C), with the Th17.1 population showing greatest fold
change (50-fold) (Fig. 6D). IFNgþ Th1 cells from blood showed no
change in frequency from ex vivo to 7 days of culture (Fig. 6A and D).
In contrast to blood, culture of T cells from SF resulted in only a 2-
fold induction of Th17 Tcells and a 4-fold induction of Th17.1 Tcells,
with Th1 cells (the largest fraction of IFNgþ T cells in SF), again
showing no change in frequency from ex vivo to 7 days of culture
(Fig. 6D).The capacity for expansion of IL-17 þ T cells during culture
correlated directly with the ability of these cells to respond to
1,25(OH)2D3, with Th17 and Th17.1 cells from blood being more
effectively suppressed by 1,25(OH)2D3 than their SF counterparts
(Fig. 7). By contrast, the lack of phenotype plasticity shown for Th1
cells and cells from SF (Fig. 6AeD), was associated with lower
sensitivity to 1,25(OH)2D3 (Fig. 7). The lack of an anti-inﬂammatory
response to 1,25(OH)2D3 in SF T cells therefore appears to be due to
the limited phenotype plasticity exhibited by these cells.4. Discussion
Vitamin D metabolites such as pro-hormone 25-
hydroxyvitamin D (25OHD) and active 1,25(OH)2D3 are detectable
in SF fromRA patients [19,33], andmonocytes isolated from SF have
been shown to actively synthesize 1,25(OH)2D3 from 25OHD
[19,34]. Thus, there is signiﬁcant potential for elevated concentra-
tions of 1,25(OH)2D3 within inﬂamed joints. In addition, VDR is
broadly expressed and present within cells from synovial tissue and
ﬂuid [35] indicating that different components of the inﬂamed joint
have the capacity to respond to 1,25(OH)2D3, in an intracrine or
paracrine fashion [18]. As recently summarized [18], multiple
in vitro studies also demonstrate anti-inﬂammatory effects of
1,25(OH)2D3 upon the immune cells that contribute to RA pathol-
ogy. However, these studies have focused on cells from the blood of
healthy controls or RA patients. The extent to which anti-
inﬂammatory responses to 1.25(OH)2D3 also occur in immune
cells from inﬂamed tissue is still poorly understood, but is never-
theless crucially important when considering the potential use of
1,25(OH)2D3 as a therapy for inﬂammatory diseases.
Th1 and Th17 cells are believed to contribute to inﬂammatory
Fig. 4. Memory T cells from synovial ﬂuid are relatively insensitive to 1,25(OH)2D3 compared to memory T cells from peripheral blood. CD45-RO þ memory T cells were
isolated from synovial ﬂuid (SF) and peripheral blood of established RA patients and stimulated with anti-CD3/CD28 beads in the presence or absence of 1,25(OH)2D3 (þ1,25D)
overnight or for 5 days. Response to 1,25(OH)2D3 was assessed by measurement of IL-17, IFNg and IL-21 by ﬂow cytometry at 5 days and relative expression of cytokines in the
presence vs the absence of 1,25(OH)2D3 calculated for n > 9 donors (A). Signiﬁcant differences were tested using Wilcoxon matched pairs tests. ns ¼ non-signiﬁcant, * ¼ P < 0.05. (B)
Effects of cell location and 20hr stimulation on VDR and RXR mRNA transcripts were examined by qPCR (B). Expression is given relative to the level in unstimulated memory cells.
Statistical signiﬁcance was tested by repeated measures two-way ANOVA. * ¼ P < 0.05, *** ¼ P < 0.001, ns ¼ not signiﬁcant. VDR expression in CD4þ T cells from blood and synovial
ﬂuid was also assessed by ﬂow cytometry for n ¼ 3 donors. Representative data for CD69 versus VDR are shown in (C).
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targets for 1,25(OH)2D3. Vitamin D supplementation may prevent,
slow or reverse inﬂammatory disease by inhibiting these T cell
subsets. The current study addressed the question of 1,25(OH)2D3
responsiveness in T cells from inﬂamed tissues.
Initial experiments (Fig.1) utilized PBMC and SFMC cultures that
included mixtures of cells including different types of T cells and
antigen-presenting cells such as dendritic cells (DC). In this setting,
and in vivo, the overall effect of 1,25(OH)2D3 on T cells may involve
indirect pathways of immunosuppression. For example, indirect
suppression of IL-17/IFNg effector T cell frequency by 1,25(OH)2D3may occur via promotion of regulatory T cell (Treg) development
[37]. In supplementary studies FoxP3þCD25 þ Treg were found to
be more abundant ex vivo in SFMC relative to PBMCs (Fig. S7A) but
there was no difference between the frequency of
FoxP3þCD25 þ cells in PBMC and SFMC cultures after CD25 stim-
ulation (Fig. S7B). Interestingly, 1,25(OH)2D3 increased expression
of CD25 in both PBMC and SFMC and CTLA-4 in SFMC alone
(Fig. S7B). However, in contrast to PBMC, 1,25(OH)2D3 did not in-
crease FoxP3þCD25 þ T cell frequencies in SFMC. It is therefore
possible that the suppressive effect of 1,25(OH)2D3 upon CD4þ Tcell
IL-17 and IFNg in PBMC cultures relative to SFMC involves, in part,
Fig. 5. 1,25(OH)2D3 suppresses cytokine expression by pre-committed Th17, Th17.1 and Th1 cells but most potently affects novel phenotype induction. CD4þ T cells from
healthy control blood were stimulated with monocytes and anti-CD3 for seven days and sorted into IL-17þIFNg- (Th17), IL-17þIFNgþ (Th17.1), IL-17-IFNgþ (Th1) or double negative
(DN) subsets using cytokine secretion assays and ﬂow cytometry. After two day culture with monocytes and anti-CD3 in the presence or absence of 1,25(OH)2D3 (þ1,25D) T cells
were re-analysed for IL-17 and IFNg expression by ﬂow cytometry. (A) Data from one donor, representative of three studied. (B) Effect of 1,25(OH)2D3 upon total IL-17 and total IFNg
expression by sorted subsets, calculated as the ratio of cells expressing the cytokine under untreated vs treated conditions.
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1,25(OH)2D3-mediated effector T cell immunosuppression PBMC
relative to SFMC.
1,25(OH)2D3 also has profound effects on antigen presenting
cells (APC) such as dendritic cells (DC) that may indirectly impact T
cell function [38]. It is also important to recognize that APC are the
main source of active 1,25(OH)2D3 from precursor 25(OH)D3 for T
cells in vivo [5,6]. Thus, the potential contribution of DC to altered
1,25(OH)2D3 sensitivity of T cells from synovial ﬂuid is likely to be
highly complex and warrants detailed future study that considers
responses to 1,25(OH)2D3 and 25(OH)D3. By isolating T cells from
SFMC and PBMC we were able to clearly demonstrate that the lack
of anti-inﬂammatory response to 1,25(OH)2D3 in mixed cell cul-
tures of SFMC involves, at least in part, an intrinsic insensitivity to
1,25(OH)2D3 by CD4þ T cells at the inﬂamed site. We therefore
predict that similar T cell insensitivity to 1,25(OH)2D3 occurs in vivo
within the inﬂamed joints of RA patients. Conversely, the lack of
effect of 1,25(OH)2D3 on IFNg production by CD8þ T cells even in
PBMC may reﬂect the fact that the IL-17þIFNgþ population of
IFNgþ cells that is the principal target for 1,25(OH)2D3 is minimal in
CD8þ T cells relative to CD4þ T cells, even under control conditions
(Fig. S1).
Both naïve (CD45RAþ) and memory (CD45ROþ) T cells wereable to respond to 1,25(OH)2D3, but inhibition of inﬂammatory
cytokines was more pronounced for naïve T cells, and became less
effective upon transition from naïve to memory. These ﬁndings
suggest that variations in the proportion of naïve to memory T cells
play a key role in deﬁning the anti-inﬂammatory impact of
1,25(OH)2D3 in vivo, especially at the inﬂammatory site where
memory T cells are the dominant T cell type [31]. Furthermore,
whilst naïve to memory transition accounted for most of the loss in
1,25(OH)2D3 effect upon SF T cells, comparing memory T cells from
blood with those from SF revealed a further decline in 1,25(OH)2D3
sensitivity in SF cells. Collectively, these data indicate that analysis
of 1,25(OH)2D3-responses using T cells from blood, even blood from
RA patients, may over-estimate the ability of vitamin D to regulate
inﬂammatory T cells in disease-affected synovial ﬂuid.
Th17 and Th1 T cell subsets not only play a critical role in the
pathophysiology of inﬂammatory diseases such as RA, they are also
pivotal to host responses to infectious pathogens such as Myco-
bacterium tuberculosis [39]. In this setting, 1,25(OH)2D3 is proposed
to be less effective in the early stages of infection, where T cells are
not chronically activated and therefore have lower levels of VDR
expression. The resulting insensitivity to 1,25(OH)2D3 during early
infection is advantageous in enablingmaintenance of inﬂammatory
T cell populations for maximal clearing of pathogenic antigen [40].
Fig. 6. Capacity for phenotype change upon stimulation is reduced in SF T cells. IL-17 and IFNg expression by CD4þ T cells from the peripheral blood and synovial ﬂuid of RA
patients was measured by ﬂow cytometry ex vivo and after anti-CD3 stimulation for seven days. (A) Representative bidirectional FACS plots of IL-17 versus IFNg in T cells from blood
and synovial ﬂuid (SF) from a single RA donor ex vivo and after 7 days of culture. (B) Summary of T cell frequencies in blood and synovial ﬂuid (SF) for multiple donors ex vivo and
after 7 days of culture. Signiﬁcant differences were tested using Wilcoxon matched pairs tests. * ¼ P < 0.05, ** ¼ P < 0.01, *** ¼ P < 0.001. (C) XY plots for frequencies of IL-17 þ and
IFNgþ CD4þ T cells ex vivo and after seven days. Diagonal lines indicate equal frequencies at each time point. (D) Pie charts summarizing the frequencies of Th17 (pale grey), Th17.1
(dark grey), Th1 (black) and double negative (DN) (white) CD4þ T cells from blood and SF ex vivo and after 7 days of culture (n ¼ 12 donors).
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activated T cells express higher levels of VDR and are therefore
more sensitive to 1,25(OH)2D3, with the principal response being
minimization of T cell activity and chronic inﬂammation [40]. Data
from the current study suggest that in chronically activated T cells
from inﬂammatory sites such as the rheumatoid joint, there is re-
instigation of 1,25(OH)2D3-insensitivity. However, in contrast to
early stage T cell responses, decreased responsiveness to
1,25(OH)2D3 in activated SF T cells does not appear to be due to
lower VDR-binding capacity for 1,25(OH)2D3: VDR expression was
increased in SF T cells ex vivo consistent with the activated
CD69 þ phenotype of these cells, and levels of VDR and co-regulator
proteins were similar for blood and SF T cells following in vitro
stimulation. Likewise differential expression of VDR and its co-
regulators did not account for the lesser effect of 1,25(OH)2D3 on
anti-inﬂammatory responses by memory vs naïve T cells.
Several single nucleotide polymorphisms (SNPs) in the VDR
gene have been associated with RA risk and severity [41], although
the functional consequence of these VDR genetic variations yet to
be deﬁned. VDR polymorphisms were not explored in this study.
Whilst it is possible that differences could inﬂuence patient
sensitivity to 1,25(OH)2D3 systemically, it is unlikely that theywould contribute to the differential 1,25(OH)2D3 sensitivity of
blood versus SF T cells as the same VDR would be expressed in
different tissues. In addition to SNPs, however, a number of 50
variant VDR transcripts have been described that are driven by
alternative promoters and display tissue speciﬁc patterns [42]. It is
therefore possible that an inﬂammation-induced switch in VDR
isoform could inﬂuence the sensitivity of SF T cells relative to blood
despite equivalent levels of VDR expression, and this will be a key
target for future studies of 1,25(OH)2D3 sensitivity in RA.
An additional feature of memory T cells versus naïve is their
commitment to phenotype as deﬁned by cytokine expression. T
cells that express multiple inﬂammatory cytokines including those
doubly expressing IL-17 and IFNg (Th17.1 cells) are regarded the
most pathogenic in inﬂammatory disease [43]. Correspondingly,
Th17.1 cells were present at increased frequency in SF T cells ex vivo
compared to blood. Previous studies into 1,25(OH)2D3 effects upon
T cell cytokine expression have used mixed cultures of cytokine-
expressing and non-expressing cells, making it impossible to
determine effects of 1,25(OH)2D3 upon phenotype-committed T
cells which, as our data on phenotype maintenance following
stimulation suggest, are more enriched in SF compared to blood. By
using novel cytokine cell capture methods to sort live Th17, Th17.1,
Fig. 7. T cell responses to 1,25(OH)2D3 correlate directly with capacity for pheno-
type change. Bidirectional plot of fold change in frequency of the population (Th17
blood (Bld), Th17 synovial ﬂuid (SF), Th17.1 Bld, Th17.1 SF, Th1 Bld, Th1 SF) after seven
day culture under control conditions versus the ratio of the population frequency in
the presence versus the absence of 1,25(OH)2D3. Correlation signiﬁcance was tested by
Pearson's analysis and the linear regression line with 95% conﬁdence interval (hashed
line) is shown.
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rent study showed that responses to 1,25(OH)2D3 are in fact highly
dependent on the commitment of T cells to a particular phenotype:
1,25(OH)2D3 treatment strongly suppressed conversion of cytokine
naïve T cells into inﬂammatory effector cells as well as the transi-
tion of one effector phenotype to another through induction of a
new cytokine. By contrast, 1,25(OH)2D3 was much less efﬁcient at
suppressing an existing T cell phenotype. T cells from SF displayed a
more committed phenotype relative to blood as indicated by only
small increases in Th17 and Th17.1 and no change in Th1 frequency
following stimulation. Thus, whilst 1,25(OH)2D3 reduced expres-
sion of IL-17 and IFNg in less phenotype-committed blood T cells by
preventing new cytokine gene expression, it was much less effec-
tive as an inhibitor of established cytokine gene expression in SF T
cells.
An important conclusion from these studies is that terminal
commitment of memory T cells to a speciﬁc phenotype, as preva-
lent in disease-affected tissues such as RA synovium, plays a central
role in attenuating anti-inﬂammatory effects of 1,25(OH)2D3. In
concert with 1,25(OH)2D3, VDR functions as a transcription factor to
regulate expression of genes such as IL-17 and IFNg that have
functional vitamin D response elements (VDRE) [44,45]. This pro-
cess is subject to genomic variation, but is also strongly inﬂuenced
by epigenetic mechanisms that may lead to intra-individual [46], or
disease-speciﬁc [32] changes in 1,25(OH)2D3-VDR signaling. Recent
studies have shown that memory T cell development is associated
with speciﬁc epigenetic signatures that strongly inﬂuence tran-
scriptional regulators [47]. Thus, it seems likely that variations in
response to 1,25(OH)2D3 according to naïve and memory state and
extent of phenotype commitment will be due to epigenetic modi-
ﬁcations that could strongly inﬂuence chromatin remodeling, and
VDRE accessibility. In future studies it will be interesting to inves-
tigate the potential use of epigenetic modulators in correcting the
1,25(OH)2D3-insensitivity characteristic of T cells from RA disease-
associated tissue.5. Conclusion
Data in the current study endorse the potential use of vitamin D
and/or 1,25(OH)2D3 in controlling the de novo generation of Th17
and Th17.1 cells that are associated with inﬂammatory disease.
However, the limited effect of 1,25(OH)2D3 on phenotype-
committed T cells from the site of inﬂammation suggests that
vitamin D supplementation is unlikely to be successful as treatment
for established active RA patients. Consistent with this hypothesis,
not all early vitamin D supplementation trials in RA have reported
positive effects of the treatment [48e50]. The fact that peripheral
blood T cells from patients were responsive to the anti-
inﬂammatory effects of 1,25(OH)2D3, and equally as responsive as
those from healthy donors, nevertheless supports a use for vitamin
D in the management of RA, either as a prophylactic or to reduce
the risk of future disease ﬂares in patients in remission. Owing to its
powerful anti-inﬂammatory effects in vitro, vitamin D supple-
mentation has been proposed as a cost-efﬁcient, ‘natural’ and low-
risk treatment strategy in multiple inﬂammatory diseases. How-
ever, since memory T cells with committed inﬂammatory pheno-
types dominate the inﬂamed tissues in multiple inﬂammatory
conditions, this study raises questions about widespread applica-
tion of vitamin D therapy in the management of inﬂammatory
diseases, especially cases of established, active disease. Further
studies are required to identify the cause of the insensitivity to
1,25(OH)2D3 at the molecular level. Strategies to overcome this and
restore 1,25(OH)2D3 sensitivity in inﬂammatory phenotype-
committed memory T cells at the inﬂamed site may provide a
novel approach to the treatment of RA and other inﬂammatory
diseases.
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